FDA Supports Alpha-Synuclein Seed Amplification Assay Biomarker for Clinical Trials in Parkinson Disease
Episode 123: Previewing Cleveland Clinic's Epilepsy Summit
Phase 3 CHARM Results Highlight Potential of IV Glibenclamide to Improve Independent Ambulation in Large Hemispheric Infarction
Multisymptomatic Care in Parkinson's Disease
This Week on NeurologyLive® — September 9, 2024
Digital Therapeutic CT-132 Meets Primary End Point in Phase 3 Study of Preventive Migraine